Certara Reports Preliminary Fourth Quarter and Full Year 2020 Results and Issues Full Year 2021 Guidance

Year-over-year 2020 revenue grew 17% to $243.5 million Raised $768.5 million in gross IPO proceeds for the Company and selling stockholders PRINCETON, N.J.—Mar. 4, 2021– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its preliminary results for the fourth quarter and full year ended December 31, 2020. Highlights: Revenue was $64.6 million … Continued

Scientific Computing World: Connecting Science

Interconnection is an imperative for the modern laboratory, and seamless integration is mandatory from the perspective of the end user, who is generally a scientist. That’s the view of Leif Pedersen, president of software at Certara (…)

Model-Informed Drug Development for Anti-Infectives: State of the Art and Future

Authors: Craig R. Rayner, Patrick F. Smith, David Andes, Kayla Andrews, Hartmut Derendorf, Lena E. Friberg, Debra Hanna, Alex Lepak, Edward Mills, Thomas M. Polasek, Jason A. Roberts, Virna Schuck, Mark J. Shelton, David Wesche, Karen Rowland‐Yeo Abstract Model‐informed drug development (MIDD) has a long and rich history in infectious diseases. This review describes foundational … Continued

Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents

Authors: Xian Pan, Felix Stader, Khaled Abduljalil, Katherine L. Gill, Trevor N. Johnson, Iain Gardner & Masoud Jamei Abstract Physiologically-based pharmacokinetic (PBPK) modelling provides an integrated framework to predict the disposition of small molecule drugs in children and is increasingly being used for dose recommendation…

Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation

By: EFPIA MID3 WorkgroupSF MarshallR BurghausV CossonSYA CheungM ChenelO DellaPasquaN FreyB HamrénL HarnischF IvanowT KerbuschJ LippertPA MilliganS RohouA StaabJL SteimerC TornøeSAG Visser Abstract This document was developed to enable greater consistency in the practice, application, and documentation of Model‐Informed Drug Discovery and Development (MID3) across the pharmaceutical industry. A collection of “good practice” recommendations are … Continued

Futurism Article: Here’s how Biden could save the coronavirus vaccine rollout

Posted on: https://futurism.com/By: Dan Robitzski It goes without saying that the coronavirus vaccine rollout in the United States has gone, well, imperfectly. Despite its ambitious goals, the Trump administration failed to communicate — and perhaps even fully develop — a COVID-19 vaccination plan until the first shots were already being shipped out…

2 of 7
Back to top
Powered by Translations.com GlobalLink OneLink Software